Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

BACKGROUND: Multiple myeloma has been shown to have substantial clonal heterogeneity, suggesting that agents with different mechanisms of action might be required to induce deep responses and improve outcomes. Such agents could be given in combination or in sequence on the basis of previous response...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Lancet Haematol
Main Authors: Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Wilson, Jamie N, Jenner, Matthew W, Cook, Gordon, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Russell, Nigel H, Gregory, Walter M, Morgan, Gareth J
Format: Artigo
Sprog:Inglês
Udgivet: Elsevier Ltd 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7043012/
https://ncbi.nlm.nih.gov/pubmed/31624047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(19)30167-X
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker